Evidence map›Paper›PMID 22895799›Full record

ArticleEuropean journal of clinical pharmacology2013

The out-of-focus bias in drug surveillance.

Markus Gnädinger, Hans-Ulrich Mellinghoff

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Markus GnädingerDepartment of General Practice, University Hospital Zurich, Zurich, Switzerland. markus.gnaedinger@hin.ch
Hans-Ulrich Mellinghoff

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeExisting drug safety systems with phase II and III studies and post-marketing surveillance by principle do not allow for the recognition of an important class of adverse drug reactions (ADRs). ADRs that are resistant to being detected reliably may a) appear as if they are age-related chronic diseases, which also manifest themselves in a high degree without drug treatment, b) arise in "old" drugs, c) arise during long-term application, and d) arise with the administration to frail and aged populations.

conclusions"Silent" and multi-factorial health problems evolving from long-term drug treatment must therefore be addressed with a systematic search strategy, as a third track along with the phase II and III studies and spontaneous reporting systems which still exist.

Indexed as

Drug-Related Side Effects and Adverse ReactionsProduct Surveillance, PostmarketingAdverse Drug Reaction Reporting SystemsBiasClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicHumansPatient SafetyPharmacovigilanceResearch DesignRisk AssessmentRisk FactorsTime FactorsTreatment Outcome

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.